Sanjivani Paranteral Ltd — Important, 15-05-2026: Company Update

Sanjivani Parenteral Limited announced its audited financial results for the fourth quarter and full financial year. For the full year, Total Income stood at ₹69.76 Cr, EBITDA reached ₹11.40 Cr (16.34% margin), and PAT was ₹6.69 Cr (9.60% margin). Revenue from operations grew to ₹68.67 Cr. The company commenced commercial production at its new IV Fluid Infusion Plant in Pune, a significant step to enhance manufacturing capabilities and expand its product portfolio. This expansion is expected to improve operational efficiency, strengthen market presence, and position the company for scalable, sustainable long-term growth.